In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Introduction Cerebrospinal fluid (CSF) biomarkers have the potential to improve the
diagnostic accuracy of Alzheimer's disease, yet there is a lack of harmonized preanalytical …

Current Alzheimer's disease (AD) diagnostics is based on clinical assessments, imaging
and neuropsychological tests that are efficient only at advanced stages of the disease. Early …

Inflammatory processes involving altered microglial activity may play a relevant role in the
pathophysiology of depressive disorders. Glial fibrillary acidic protein (GFAP) and calcium …

Objectives The utility of cerebrospinal fluid (CSF) CXCL13 for diagnosis of acute Lyme
neuroborreliosis (LNB) has been debated and the test is not yet routinely performed. This …

Diagnosis of Parkinson's disease (PD) relies on clinical history and physical examination,
but misdiagnosis is common in early stages. Identification of biomarkers for PD may allow …

Turnaround time (TAT), which doctors frequently use as the benchmark for laboratory
performance, is a typical way to communicate timeliness. It also acts as a quality indicator to …

Introduction Freeze-thaw instability may contribute to preanalytical variation in blood-based
biomarker studies. We investigated the effects of up to four freeze-thaw cycles on single …

A panel of cerebrospinal fluid (CSF) biomarkers including total Tau (t-Tau), phosphorylated
Tau protein at residue 181 (p-Tau) and β-amyloid peptides (Aβ 42 and Aβ 40), is frequently …

Background: The unbiased amyloid, tau, and neurodegeneration (A/T/N) classification is
designed to characterize individuals in the Alzheimer continuum and is currently little …